Skip to main content
. 2020 Jul 7;11:1406. doi: 10.3389/fimmu.2020.01406

Figure 4.

Figure 4

Tofacitinib treatment alter Mo-DC differentiation and function in RA and PsA patients. Monocytes from PsA (n = 9) or RA (n = 12) patients were differentiated GM-CSF/IL-4 in the presence of absence of Tofacitinib 1 μM (or DMSO). (A) 7 day post-differentiation. CD209, surface differentiation marker, and CD14, monocyte markers, were evaluated by flow cytometry in the CD11c+ population. (B) 1, 2, and 3 days post-differentiation. CD209 surface differentiation marker was evaluated in the CD11c+ population in PsA (n = 3) and RA (n = 6) patients. (C) 1 day post-differentiation, CD40 and CD86 activation markers were evaluated in the CD11c+ population in PsA (n = 4) and RA (n = 4) patients. (D) 7 day post-differentiation, endocytosis was analyzed as per Figure 3 in Mo-DC from PsA (n = 5) and RA (n = 6) patients. Data are represented as mean ±SEM and differences among groups were evaluated with two-way ANOVA with Tukey post-test. *p < 0.05, **p < 0.01, ***p < 0.001 (differences between Mo-DC with and without TOFA within the same group) and #p < 0.05, ##p < 0.01, ###p < 0.001 (differences between RA and PsA samples).